PubMed Health⌕ Search

Biomedical subjects

J D Fernstrom

Publications and source records attributed to J D Fernstrom.

At least 55 records · Page 3Linked to original sources
PubMed1990

Effects of L-tryptophan and other amino acids on electroencephalographic sleep in the rat.

Electroencephalographic sleep was quantitated in adult male Sprague-Dawley rats following single injections of the methylesters of tryptophan, valine or alanine. The amino acids were administered at the onset of the daily light period (09.00 h); electrographic data were collected for the succeeding 6-h period. Saline served as the injection control, and fluoxetine, a serotonin-reuptake blocker, as a positive control. The injection of tryptophan methylester (125 mg/kg) caused a delay in rapid eye movement (REM) sleep onset, and significantly reduced the amount of REM sleep during the first 2 h postinjection. Tryptophan produced no effect on sleep onset, nor did it influence total sleep time. Fluoxetine (2.5 mg/kg) produced similar effects, as previously observed. The methylesters of valine and alanine were without effect on REM sleep, when injected at a molar dose equivalent to that for tryptophan. No consistent effects of any of the test substances were noted on non-REM (NREM) sleep or waking time, or on any of the other sleep indices quantitated. Together, the data indicate that tryptophan selectively reduces REM sleep; the effect is not due to a non-specific action of amino acids or their methylesters. The effect on REM sleep may be the consequence of a tryptophan-induced stimulation of 5-HT synthesis and release, since it is like that produced by fluoxetine, a drug that enhances transmission across serotonin synapses.

Alanine↗
PubMed1990

Effect of an oral tryptophan/carbohydrate load on tryptophan, large neutral amino acid, and serotonin and 5-hydroxyindoleacetic acid levels in monkey brain.

Plasma and brain levels of tryptophan and other large neutral amino acids, and brain levels of serotonin and 5-hydroxyindoleacetic acid (5 HIAA) were measured in groups of adult cynomolgus monkeys 1 hr after they ingested one of four doses of a tryptophan-carbohydrate mixture. The doses had been administered once daily for 13 weeks. Dose-related increments occurred in plasma tryptophan, the plasma ratio of tryptophan to the sum of other large neutral amino acids, and in brain tryptophan levels. In contrast, the plasma ratios and brain levels of the other neutral amino acids each declined. Serotonin and 5 HIAA levels increased significantly, and in a dose-related manner in the brainstem and striatum, but not in cortex or hypothalamus. The results suggest that while tryptophan administration can stimulate serotonin production in primate brain, the effect may be restricted to certain brain regions. They also suggest that the transport of the large neutral amino acids into brain occurs via a competitive mechanism similar to that for other mammals.

Administration, Oral↗
PubMed1990

Effect of 8-hydroxy-2-(di-n-propylamino)-tetralin on the tryptophan-induced increase in 5-hydroxytryptophan accumulation in rat brain.

The injection of 8-hydroxy-2-(di-n-propylamino)-tetralin [8-OH-DPAT]reduced 5-hydroxytryptophan accumulation in vivo in rat cerebral cortex, hypothalamus and brainstem. Brain tryptophan levels were unaffected. Dose-related increases in 5-hydroxytryptophan accumulation produced by single injections of L-tryptophan (0, 25, 75 mg/kg ip) were substantially diminished by pretreatment with 8-OH-DPAT. The drug did not affect the tryptophan-induced increments in brain tryptophan level. Since 8-OH-DPAT is known to reduce the activity of serotonin neurons in vivo, these results suggest that when serotonin neurons are relatively inactive, the ability of an injection of tryptophan to stimulate serotonin synthesis is greatly attenuated.

5-Hydroxytryptophan↗
PubMed1990

In vivo somatostatin, vasopressin, and oxytocin synthesis in diabetic rat hypothalamus.

The in vivo labeling of somatostatin-14, somatostatin-28, arginine vasopressin, and oxytocin was studied in rat hypothalamus after third ventricular administration of [35S]cysteine to streptozotocin-diabetic and normal rats. Immunoreactive somatostatin levels in hypothalamus were unaffected by diabetes, as was the incorporation of [35S]cysteine into hypothalamic somatostatin-14 and somatostatin-28. In contrast, immunoreactive vasopressin levels in hypothalamus and posterior pituitary (and oxytocin levels in posterior pituitary) were below normal in diabetic rats. Moreover, [35S]cysteine incorporation into hypothalamic vasopressin and oxytocin (probably mainly in the paraventricular nucleus because of its proximity to the third ventricular site of label injection) was significantly above normal. The increments in vasopressin and oxytocin labeling were reversed by insulin administration. In vivo cysteine specific activity and the labeling of acid-precipitable protein did not differ between normal and diabetic animals; effects of diabetes on vasopressin and oxytocin labeling were therefore not caused by simple differences in cysteine specific activity. These results suggest that diabetes 1) does not influence the production of somatostatin peptides in hypothalamus but 2) stimulates the synthesis of vasopressin and oxytocin. For vasopressin at least, the increase in synthesis may be a compensatory response to the known increase in its secretion that occurs in uncontrolled diabetes.

Animals↗
PubMed1990

A defect in sodium-dependent amino acid uptake in diabetic rabbit peripheral nerve. Correction by an aldose reductase inhibitor or myo-inositol administration.

A myo-inositol-related defect in nerve sodium-potassium ATPase activity in experimental diabetes has been suggested as a possible pathogenetic factor in diabetic neuropathy. Because the sodium-potassium ATPase is essential for other sodium-cotransport systems, and because myo-inositol-derived phosphoinositide metabolites regulate multiple membrane transport processes, sodium gradient-dependent amino acid uptake was examined in vitro in endoneurial preparations derived from nondiabetic and 14-d alloxan diabetic rabbits. Untreated alloxan diabetes reduced endoneurial sodium-gradient dependent uptake of the nonmetabolized amino acid 2-aminoisobutyric acid by greater than 50%. Administration of an aldose reductase inhibitor prevented reductions in both nerve myo-inositol content and endoneurial sodium-dependent 2-aminoisobutyric acid uptake. Myo-inositol supplementation that produced a transient pharmacological elevation in plasma myo-inositol concentration, but did not raise nerve myo-inositol content, reproduced the effect of the aldose reductase inhibitor on endoneurial sodium-dependent 2-aminoisobutyric acid uptake. Phorbol myristate acetate, which acutely normalizes sodium-potassium ATPase activity in diabetic nerve, did not acutely correct 2-aminoisobutyric uptake when added in vitro. These data suggest that depletion of a small myo-inositol pool may be implicated in the pathogenesis of defects in amino acid uptake in diabetic nerve and that rapid correction of sodium-potassium ATPase activity with protein kinase C agonists in vitro does not acutely normalize sodium-dependent 2-aminoisobutyric acid uptake.

Amino Acids↗
PubMed1989

In vivo tyrosine hydroxylation rate in retina: effects of phenylalanine and tyrosine administration in rats pretreated with p-chlorophenylalanine.

p-Chlorophenylalanine was administered to rats to inhibit hepatic phenylalanine hydroxylase activity. Two days later, phenylalanine injection was noted to produce substantial increases in serum phenylalanine levels, and relatively modest increments in serum tyrosine levels. Rats injected with p-chlorophenylalanine 2 days earlier showed a normal light-induced activation of retinal tyrosine hydroxylase activity in vivo, measured as dihydroxyphenylalanine accumulation following pharmacologic inhibition in vivo of aromatic L-amino acid decarboxylase activity. In addition, tyrosine injection into p-chlorophenylalanine-treated rats in the light produced anticipated increments in retinal tyrosine hydroxylation rate, showing the enzyme to be functionally normal. The acute administration of phenylalanine (62.5-500 mg/kg i.p.) to p-chlorophenylalanine-treated rats produced dose-related increments in retinal phenylalanine. In vivo tyrosine hydroxylation rate in retina was normal at all doses below 300 mg/kg. However, at the highest dose (500 mg/kg), when retinal phenylalanine levels were almost 5-times normal tyrosine hydroxylation rate consistently fell (to about half-normal values). These results demonstrate that very large elevations in tissue phenylalanine levels do not stimulate tyrosine hydroxylation in vivo, and that at extremely high levels phenylalanine inhibits tyrosine hydroxylation rate.

Animals↗
PubMed1989

Oral aspartame and plasma phenylalanine: pharmacokinetic difference between rodents and man, and relevance to CNS effects of phenylalanine. Short note.

The ingestion of aspartame, a phenylalanine-containing dipeptide, raises plasma phenylalanine levels. These increments are much greater in humans than rats, because the rat hydroxylates phenylalanine five times faster than man. Accordingly, dose comparisons of aspartame (or phenylalanine) between humans and rats have usually been corrected by a factor of five. Recently, a correction factor of sixty has been proposed (Wurtman and Maher, 1987); the rationale is based on a novel calculation of competitive phenylalanine transport into brain. An analysis of the logic behind this postulation reveals there to be no basis for accepting the higher dose conversion of 60 between rat and man.

Administration, Oral↗
PubMed1988

A microcomputer-based sleep system: data acquisition and system calibration programs.

A data acquisition program is described for the Apple II series of microcomputers that allows for continuous, direct monitoring of electrographic elements from cortical, hippocampal and muscle leads from rats. The program detects cortical delta waves and sigma activity, hippocampal theta activity and electromyographic activity. The detected elements are counted and stored in memory at 15 second intervals (bins). Every three hours, the data are transferred to disks for permanent storage and off-line analysis.

Animals↗
PubMed1988

Carbohydrate ingestion and brain serotonin synthesis: relevance to a putative control loop for regulating carbohydrate ingestion, and effects of aspartame consumption.

The ingestion of a meal of carbohydrates by fasting rats rapidly increases brain tryptophan level and serotonin (5-HT) synthesis. The rise in brain tryptophan level follows from an increase in tryptophan transport into brain, the consequence of an insulin-induced reduction in the blood levels of several amino acids that compete with tryptophan for brain uptake. In contrast, ingesting protein with carbohydrate does not stimulate brain tryptophan uptake or 5-HT synthesis, because the blood levels of tryptophan's transport competitors are increased, not reduced. These observations form the biochemical basis of a current proposal for a regulatory loop governing meal-to-meal appetite for carbohydrates. This review briefly analyzes the experimental basis for the carbohydrate appetite regulatory loop, and finds it wanting. It also considers the proposal that the ingestion of the artificial sweetener aspartame might disrupt the putative regulatory loop for carbohydrate intake regulation, and thus promote rather than help to limit carbohydrate appetite, and finds this hypothesis unrealistic as well. In general, the conclusion is that while single meals do readily influence brain tryptophan uptake and 5-HT synthesis, it is presently unclear what role such neurochemical effects of food ingestion have in the control of specific appetites.

Amino Acids↗
PubMed1987

Short-term effects of fluoxetine and trifluoromethylphenylpiperazine on electroencephalographic sleep in the rat.

Fluoxetine and trifluoromethylphenylpiperazine (TFMPP) were studied for their short-term effects on electroencephalographic sleep in male rats. Following single injection, each drug produced a sizeable, dose-related suppression of rapid-eye-movement (REM) sleep that persisted for 4-5 h (fluoxetine, 0.625-5 mg/kg; TFMPP, 0.10-1.25 mg/kg). TFMPP also consistently increased non-REM (NREM) sleep during the second hour after drug injection, though this effect was not dose-related (it was seen at all doses tested). Fluoxetine produced small effects on NREM sleep that varied non-systematically with dose and time after drug injection. TFMPP, but not fluoxetine, also increased at all doses the number of delta waves per minute of NREM sleep in the second hour. A structural analog of TFMPP that is inactive at serotonin (5-HT) receptors [4-(m-trifluoromethylphenyl)piperadine; LY97117] was also tested, and found to be devoid of effects on NREM and REM sleep. Both fluoxetine (a 5-HT reuptake blocker) and TFMPP (a 5-HT agonist) enhance transmission across 5-HT synapses, though by different mechanisms. Because they have the common effect of suppressing REM sleep, and in a dose-related manner, the data support the notion that 5-HT neurons in the brain, when active, can suppress REM sleep.

Animals↗
PubMed1987

Protein consumption increases tyrosine concentration and in vivo tyrosine hydroxylation rate in the light-adapted rat retina.

The ingestion of a single, 40% protein meal increased serum and retinal tyrosine levels and stimulated retinal tyrosine hydroxylation rate in light-adapted rats. Consumption of a similar, protein-free meal elicited none of these effects. The results thus indicate for retinal dopamine neurons that physiologically induced increases in tyrosine level can readily stimulate in vivo tyrosine hydroxylation rate.

Amino Acids↗
PubMed1987

Twenty-four-hour variations in rat blood and brain levels of the aromatic and branched-chain amino acids: chronic effects of dietary protein content.

Groups of young adult, male rats were given free access for 12 weeks to a single diet containing either 12%, 24%, or 40% protein (dry weight). At the end of this time, six rats from each diet group were killed every four hours throughout a single 24-hour period, and blood samples and brains were obtained for quantitation of several of the large neutral amino acids (LNAAs). The blood level of each LNAA varied significantly as a function of time of day (tending to be lower during the day than at night) and as a function of dietary protein content (typically rising as protein intake increased). Except for tyrosine and valine, the serum concentration ratio of each LNAA to the sum of the other LNAA (previously reported to be a good predictor of the competitive uptake of each LNAA into brain) and the brain level of each LNAA showed unremarkable variations with time of day and dietary protein content. In contrast, the serum ratios and brain levels of tyrosine and valine did show notable variations at night as a function of dietary protein intake. Together, the results show that within a chronic physiologic range of protein intakes, the serum ratios and brain levels of several large neutral amino acids, particularly tryptophan, bear no relationship to dietary protein level. Though good correlations between these parameters and protein intake were obtained for valine and tyrosine, their physiologic/metabolic significance, if any, is unknown. In general, the data do not support the broad, unvalidated use of serum LNAA ratios in chronic settings as predictors of brain LNAA levels.

Amino Acids↗
PubMed1987

In vivo biosynthesis of arginine vasopressin and oxytocin in hypothalami from intact and hypophysectomized rats.

The rates of incorporation of [35S]cysteine into arginine vasopressin (AVP) and oxytocin (OXT) were studied concurrently in hypothalami from intact and hypophysectomized male rats. After label injection into the third ventricle, rats were killed 0.5, 1, 2, 4, or 8 h later. The hypothalamic peptides were quantitated by specific RIA and separated by HPLC to allow quantitation of label incorporation into each peptide. In intact rats, labeling of both OXT and AVP rose rapidly to peak at 2 h; thereafter, radioactivity in both peptides declined slowly to 8 h. In hypophysectomized rats, labeling of AVP fell below that in intact animals at all time points. Labeling of OXT was somewhat below normal 2 h after label injection, but considerably above normal at 4 and 8 h. For comparison, label incorporation into somatostatin-14 (SRIF-14) and somatostatin-28 (SRIF-28) was also studied in the same animals. In intact rats, labeling of both SRIF peptides rose slowly to maximal values at 8 h. In hypophysectomized animals, labeling of each peptide was reduced substantially at all times tested. Endogenous cysteine specific activity and protein specific activity did not differ between intact and hypophysectomized animals. Immunoreactive levels of AVP and OXT in the hypothalamus were unaffected by hypophysectomy, though total SRIF-like immunoreactivity was depressed. Together these results suggest that hypothalamic neurons synthesize OXT and AVP at rates much faster than those for the SRIF peptides, and that hypophysectomy has differential effects on the syntheses of cysteine-containing peptides in the hypothalamus. Specifically, the syntheses of SRIF-14 and SRIF-28 appear to be sizeably reduced in hypophysectomized rats, while that of AVP only modestly diminished. OXT synthesis may be increased.

Animals↗
PubMed1986

Effect of tyrosine administration on dopa accumulation in light- and dark-adapted retinas from normal and diabetic rats.

The interaction of tyrosine concentration and lighting on in vivo dihydroxyphenylalanine (dopa) accumulation rate was studied in retinas of normal and diabetic rats. In both groups of rats, dopa accumulation and in vitro hydroxylase activity were higher in retinas exposed to light than in those adapted to darkness. In light-adapted diabetic rats, though, retinal tyrosine level, dopa accumulation, and in vitro tyrosine hydroxylase activity were all below normal. In both normal and diabetic rats exposed to light, tyrosine injection raised retinal tyrosine concentrations and stimulated dopa accumulation. Injection of tyrosine into dark-adapted rats raised retinal tyrosine level but did not enhance dopa accumulation. Together, these results suggest that in vivo retinal amacrine cells will vary their dopa accumulation rate as a function of substrate supply, but only in the light, when tyrosine hydroxylase is activated. They further indicate that dopa accumulation rate remains sensitive to tyrosine supply in the light-activated diabetic retina.

Adaptation, Ocular↗
PubMed1986

Effect of hypophysectomy on somatostatin-14 and somatostatin-28 biosynthesis in the rat hypothalamus.

The in vivo incorporation of [35S]cysteine into hypothalamic somatostatin-28 was found to be substantially below normal in hypophysectomized rats. A smaller reduction in label incorporation into arginine vasopressin was also observed, while incorporation into acid-precipitable protein was normal. The diminution in somatostatin biosynthesis presumably reflects the absence of pituitary growth hormone secretion, while that in vasopressin synthesis may reflect the loss or disruption of vasopressin-producing cells.

Animals↗